Immunotherapy is the cornerstone for addressing the inflammatory component of IgLON5-IgG disease as there are currently no effective treatments for the neurodegenerative component though putative therapeutic targets have been identified in the context of other tauopathies [47,48]. This evidence concerns the gene IGLON5 and tauopathy.